Literature DB >> 16282044

Medication-overuse headache.

Lutz Pageler1, Irini Savidou, Volker Limmroth.   

Abstract

Medication-overuse headache (MOH) can be caused by almost all anti-headache drugs including analgesics, ergots, triptans, and combined preparations The prevalence of chronic daily headache (CDH) appears to be between 2% and 4% in the general population. Current epidemiologic studies suggest that MOH accounts for approximately 50% of these cases. The pathophysiology of MOH remains unclear. The only therapy is withdrawal from the overused substances. Prednisone decreases the duration of headache in the first days of withdrawal therapy. The only strategy to reduce the prevalence of MOH is to prevent the development of MOH in the first place by restriction of anti-headache drugs and constant education of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282044     DOI: 10.1007/s11916-005-0023-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  38 in total

1.  Medication overuse headache: rates and predictors for relapse in a 4-year prospective study.

Authors:  Z Katsarava; M Muessig; A Dzagnidze; G Fritsche; H C Diener; V Limmroth
Journal:  Cephalalgia       Date:  2005-01       Impact factor: 6.292

2.  The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache.

Authors:  S D Silberstein; J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; T J Steiner
Journal:  Cephalalgia       Date:  2005-06       Impact factor: 6.292

3.  Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.

Authors:  J Castillo; P Muñoz; V Guitera; J Pascual
Journal:  Headache       Date:  1999-03       Impact factor: 5.887

4.  Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache.

Authors:  H C Diener; J Haab; C Peters; S Ried; J Dichgans; A Pilgrim
Journal:  Headache       Date:  1991-04       Impact factor: 5.887

5.  Is overuse of sumatriptan a problem? A population-based study.

Authors:  D Gaist; J Hallas; S H Sindrup; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  New guidelines for the management of migraine in primary care.

Authors:  A J Dowson; S Lipscombe; J Sender; T Rees; D Watson
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

7.  Prevalence and description of chronic daily headache in the general population in France.

Authors:  Michel Lantéri-Minet; Jean-Paul Auray; Abdelkader El Hasnaoui; Jean-François Dartigues; Gérard Duru; Patrick Henry; Christian Lucas; André Pradalier; Guy Chazot; Anne-Françoise Gaudin
Journal:  Pain       Date:  2003-03       Impact factor: 6.961

8.  Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up.

Authors:  S J Wang; J L Fuh; S R Lu; C Y Liu; L C Hsu; P N Wang; H C Liu
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

9.  Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache?

Authors:  G G Tribl; P Schnider; C Wöber; S Aull; A Auterith; K Zeiler; P Wessely
Journal:  Cephalalgia       Date:  2001-07       Impact factor: 6.292

10.  [Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache].

Authors:  G Haag; H Baar; K H Grotemeyer; V Pfaffenrath; M J Ribbat; H C Diener
Journal:  Schmerz       Date:  1999-02-18       Impact factor: 1.107

View more
  1 in total

1.  Drug-dependence behaviour and outcome of medication-overuse headache after treatment.

Authors:  Ilenia Corbelli; Stefano Caproni; Paolo Eusebi; Paola Sarchielli
Journal:  J Headache Pain       Date:  2012-10-18       Impact factor: 7.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.